Arca
Skip to content
Tools
Tools

Cystic fibrosis

Drug research and approvals for cystic fibrosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 153 studies of cystic fibrosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 79 drug trials for it since 2013, FDA has 30 approved and 93 open orphan designations naming it, and the EU has 11 authorised medicines for it.

  • Recruiting worldwide: 153
  • Trials authorized in Canada: 79
  • FDA orphan approvals: 30
  • EU medicines: 11

Recruiting now

Newest posted first, of 153 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 12

Phase 3 12 of 15

Phase 2 12 of 58

Phase 1 or earlier 12 of 39

How its trials ended

1,522 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 364 whose ending is known, 45% met their primary endpoint, 10% missed it and 45% stopped early.

  • Completed, result not reported77651%
  • Ongoing24616%
  • Met its primary endpoint16211%
  • Status unknown1369%
  • Stopped: other or unclear976%
  • Stopped: enrollment or feasibility433%
  • Missed its primary endpoint372%
  • Stopped: lack of efficacy101%
  • Stopped: sponsor or business decision91%
  • Stopped: funding5<1%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 79; search them all in Canada trials
Jul 3, 2026A phase 2, multicenter, randomized, active-controlled study to assess the safety and efficacy of ANG003 at two different dose levels in subjects with exocrine…ANG003 (lipase V325, protease, amylase) / CreonAnagram Therapeutics, Inc.Pending
Dec 19, 2025A multicentre, lnterventional, non-inferiority study comparing a pancreatic enzyme replacement therapy formulation to standard of care, creon®, in the…EN311EneapharmPending
Mar 4, 2025A phase 3 study evaluating the pharmacokinetics, safety, and tolerability of VX-121 / tezacaftor/ deutivacaftor triple combination therapy in cystic fibrosis…Vanzacaftor (VX-121)-tezacaftor-deutivacaftor (VX-561) /…Vertex PharmaceuticalsOngoing
Sep 3, 2024A phase 3, open-label study evaluating the long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis subjects 12 months of age and…Elexacaftor-tezacaftor-ivacaftor/ IvacaftorVertex PharmaceuticalsOngoing
Jul 10, 2024A phase 2a, randomized, placebo-controlled, double blind multiple ascending dose study in patients with cystic fibrosis carrying the 3849 +10 kb c->t mutation…SPL84Splisense, LtdOngoing
Jun 23, 2023A phase 1/2 dose-escalation study evaluating the safety, tolerability, and efficacy of VX-522 in subjects 18 years of age and older with cystic fibrosis and a…VX-522 / Ivacaftor / Zenhale / Advair / Salbutamol / Bricanyl turbuhalerVertex PharmaceuticalsOngoing
Apr 21, 2023A phase 3, open-label study evaluating the pharmacokinetics, safety, and tolerability of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis subjects 12 to…Elexacaftor-tezacaftor-ivacaftor / IvacaftorVertex PharmaceuticalsClosed
Dec 8, 2022A phase 3 open-label study evaluating the long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis subjects with NON-F508DEL cftr…Elexacaftor (VX-445)-tezacaftor-ivacaftor / IvacaftorVertex PharmaceuticalsOngoing
Sep 28, 2022A phase 3, open-label study evaluating the long-term safety and efficacy of VX-121/tez/d-iva combination therapy in subjects with cystic fibrosisVanzacaftor-tezacaftor-deutivacaftorVertex PharmaceuticalsOngoing
May 31, 2022A phase 3 double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of elx/tez/iva in cystic fibrosis subjects 6 years of age and…Elexacaftor-tezacaftor- ivacaftor/ IvacaftorVertex PharmaceuticalsOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 123
Mar 27, 2026AlyftrekTreatment of cystic fibrosis (CF) in adult and pediatric patients 6 years of age and older who have a clinical diagnosis of CF and who have…Vertex Pharmaceuticals IncorporatedApproved
Mar 27, 2026TrikaftaTreatment of cystic fibrosis (CF) in adult and pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have…Vertex Pharmaceuticals IncorporatedApproved
Dec 20, 2024AlyftrekTreatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive…Vertex Pharmaceuticals IncorporatedApproved
Dec 20, 2024TrikaftaTreatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis…Vertex Pharmaceuticals IncorporatedApproved
May 3, 2023KalydecoTreatment of cystic fibrosis (CF) in patients age 1 month and older who have at least one mutation in the CFTR gene that is responsive to…Vertex Pharmaceuticals, Inc.Approved
Apr 26, 2023TrikaftaTreatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis…Vertex Pharmaceuticals IncorporatedApproved
Sep 2, 2022OrkambiTreatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR geneVertex Pharmaceuticals Inc.Approved
Jun 8, 2021TrikaftaTreatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis…Vertex Pharmaceuticals IncorporatedApproved
Dec 21, 2020TrikaftaTreatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis…Vertex Pharmaceuticals IncorporatedApproved
Dec 21, 2020SymdekoTreatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one…Vertex Pharmaceuticals Inc.Approved
Dec 21, 2020KalydecoTreatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance…Vertex Pharmaceuticals, Inc.Approved
Oct 30, 2020Bronchitol®As add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use…Pharmaxis Europe LimitedApproved
Sep 24, 2020KalydecoKALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene…Vertex Pharmaceuticals, Inc.Approved
Oct 21, 2019TrikaftaTRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation…Vertex Pharmaceuticals IncorporatedApproved
Jun 21, 2019SymdekoSYMDEKO? is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del…Vertex Pharmaceuticals Inc.Approved

Medicines authorised in the EU

Newest first
Jun 30, 2025AlyftrekDeutivacaftor / tezacaftor / vanzacaftor · orphanVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Aug 21, 2020KaftrioIvacaftor; tezacaftor; elexacaftor · orphanVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Feb 18, 2019Vantobra (previously Tobramycin PARI)TobramycinPari Pharma GmbHEMA ↗
Oct 31, 2018SymkeviTezacaftor; ivacaftor · orphanVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Nov 19, 2015OrkambiLumacaftor; ivacaftorVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Mar 25, 2015QuinsairLevofloxacinChiesi Farmaceutici S.p.AEMA ↗
Jul 23, 2012KalydecoIvacaftorVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Apr 13, 2012BronchitolMannitolPharmaxis Europe LimitedEMA ↗
Feb 13, 2012ColobreatheColistimethate sodiumEssential Pharma LimitedEMA ↗
Jul 20, 2011Tobi PodhalerTobramycinViatris Healthcare LimitedEMA ↗
Sep 21, 2009CaystonAztreonamGilead Sciences Ireland UCEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.